The global brachytherapy market size is expected to reach USD 452.3
million by 2025. It is projected to register a CAGR of 4.8% over the
forecast period.

Technological advancements and R&D investments by key market players are
some of the major growth drivers. In August 2017, Salutaris Medical
Devices launched the trial of brachytherapy treatment for neovascular
age-related macular degeneration. The trial is to study surgeons’ ease
in using SalutarisMD system (SMD-DA system) along with the anti-VEGF
treatment regimen and the safety of the same.

According to the International Agency for Research on Cancer, in 2015,
more than 15 million people suffered from cancer while 8.8 million
deaths were caused by the disease worldwide. This number is expected to
rise to 24 million by 2035. It is also estimated that 23.6 million new
cancer cases will be diagnosed by 2030.

According to the American Brachytherapy Society, safety, and efficacy of
brachytherapy treatment over other cancer treatments, such as
chemotherapy and surgery, is expected to boost the market. In addition,
favorable reimbursement guidelines are expected to contribute to the
rising adoption of brachytherapy.

The Center for Medicare and Medicaid (CMS) implemented new High-Dose
Rate (HDR) treatment delivery codes in 2016. The final rates for 2017
included an increase of approximately 5% to 6% in payments. Increasing
usage of these technologies and the presence of favorable reimbursement
policies in developing countries are expected to further fuel growth of
the brachytherapy market.

Further key findings from the study suggest:

In 2017, HDR brachytherapy held the largest market share in terms of
revenue. The segment is also expected to witness the fastest CAGR over
the forecast period due to the growing incidence of breast cancer,
unhealthy lifestyle, rising R&D investments, and the introduction of
technologically improved treatment solutions

Application segment is further divided into prostate cancer, breast
cancer, gynaecological cancer, and other types of cancer. Breast
cancer is expected to witness the fastest CAGR over the forecast period

North America held the dominant market in terms of revenue in 2017. On
the other hand, Asia Pacific is expected to witness the fastest CAGR
over the forecast period